Skip to content
Catalyst

PapersPMID:21208586

L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study.

The Journal of clinical psychiatry2011The record ↗

findings
2
compound
1
endpoints
2
  1. Finding, very limited evidencelowersPANSS positive subscale score
  2. Finding, very limited evidencelowersPANSS general psychopathology subscale score
Study, every finding
RCT · 8 weeks
Dose studied, every finding
L-theanine 400 mg/d added to ongoing antipsychotic
Population, every finding
Chronic schizophrenia or schizoaffective disorder (DSM-IV); antipsychotic treatment continued in both arms as background; 8-week 2-center trial; PANSS 3-dimensional model

Study record

Design
randomised controlled trial
Species
human
Population
patients with chronic DSM-IV schizophrenia or schizoaffective disorder on antipsychotic treatment
Participants
60
Comparator
placebo
Duration
56 days
Endpoints measured
8